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Eye Institute, National Institutes of Health, Bethesda, MTo understand the regulatory mechanisms governing glucocorticoid-mediated MYOC induction in human
trabecular meshwork (HTM) cells, the expression and degradation ofMYOCmRNA were quantiﬁed in HTM
cells by Northern blot analysis, and the transcriptional activity of constructs containing variable lengths
of putativeMYOC promoters was assessed by luciferase reporter assay. Here, we conﬁrmed thatMYOC is a
delayed secondary glucocorticoid-responsive gene by demonstrating that its transcription was not initi-
ated immediately by the addition of dexamethasone (DEX) and was completely inhibited by treatment
with cycloheximide. In addition, we demonstrated that MYOC mRNA is degraded very slowly, with
approximately half persisting for at least 4 days, suggesting that its mRNA is intrinsically quite stable.
Promoter analysis of up to 5271 base pairs upstream of MYOC revealed that luciferase induction by
DEX was increased by 280 ± 34% in HTM cells. Moreover, DEX induction required the region between base
pairs 2548 and 1541. However, the putative regulatory element exhibited little activity in other cell
lines, including TM-5, 293A, SH-SY5Y, and human retinal pigment epithelium (RPE) cells. To our knowl-
edge, this study provides the ﬁrst evidence for the presence of a cis-acting region for secondary glucocor-
ticoid responsiveness in the 50-ﬂanking sequences ofMYOC. It will be a major step towards understanding
the expression pattern of MYOC in HTM cells and TM tissue.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
The long-term use of topical or systemic steroids results in ocu-
lar hypertension with glaucoma, known as steroid-induced glau-
coma (SIG), in a subset of the normal population (Francois,
1954). SIG is clinically identical to primary open-angle glaucoma
(POAG), which affects nearly half the estimated 67 million people
with glaucoma worldwide (Quigley, 1996). Both SIG and POAG
are characterized by excavation of the optic disk, visual ﬁeld deﬁ-
cits, and optic nerve cupping, and have been shown to be caused by
elevated intraocular pressure (IOP) due to increased outﬂow resis-
tance through the trabecular meshwork (TM) (Armaly, 1963a,
1963b, 1966).
The long-term exposure of TM cell cultures to dexamethasone
(DEX) leads to the upregulation of a series of proteins. One of these
is an acidic glycoprotein of 504 amino acids, originally referred to
as trabecular meshwork-inducible glucocorticoid response (TIGR)
(Nguyen et al., 1998, Polansky, Kurtz, Alvarado, Weinreb, &
Mitchell, 1989). The protein is currently known as myocilin, soll rights reserved.
elopmental Biology, National
L 20892, United States.named because its NH2-terminal domain resembles nonmuscle
myosin (Kubota et al., 1997). The gene encoding myocilin, MYOC,
is localized on chromosome 1q23-q25 (GLC1A), and is mutated in
more than 10% of cases of juvenile open-angle glaucoma (OAG)
and in 3–4% of some forms of adult-onset POAG (Alward et al.,
1998, Fingert et al., 1999, Stone et al., 1997).
Although a great deal has been learned in recent years about the
mechanisms by which mutations in MYOC cause glaucoma, much
remains to be learned about the roles played by increased levels
ofMYOC in the TM of steroid-responsive individuals. It was initially
hypothesized thatMYOC upregulation might be a cause or an effect
of IOP elevation in SIG because the proﬁle of MYOC induction by
DEX is in dose- and time-dependent manner very similar to the
course of SIG development (Nguyen et al., 1998; Polansky et al.,
1997). However, evidence supporting the link between MYOC
induction and OAG development has not as yet been available.
The present study was undertaken to characterize DEX-induced
MYOC expression and to search for DEX-responsive cis-acting ele-
ments in human trabecular meshwork (HTM) cells. The character-
ization of MYOC expression, together with the identiﬁcation of its
regulatory element(s), will be a useful ﬁrst step in understanding
the putative relationship between DEX-mediated MYOC induction
and steroid-induced ocular hypertension.
Table 1
Primers used in the ampliﬁcation of promoter sequence of MYOC.
Designation Size (bp) Sequence (50 to 30)
367 432 GGTACCAATGAGTTTGCAGAGTGAATG
GCTAGCTGCAGAGGCTTGGTGAGGCT
684 749 GGTACCGAGTTCCCCAGATTTCACCA
GCTAGCTGCAGAGGCTTGGTGAGGCT
1541 1606 GGTACCGCACAAGGGCAATCCCGTTT
GCTAGCTGCAGAGGCTTGGTGAGGCT
2548 1230 GGTACCAGGGTGTGCATGGGTTTT
TGGTTCTGCAGTTAAGCCTG
3531 1085 GGTACCACCATGCTTTTGTGGTAAG
CTCCAGTCACTTCTTCCGTG
4351 942 GGTACCACCATTTTAAGTATAAAACA
CAAGGAGTCTCTGGGGTATG
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2.1. Cell culture
Primary HTM cells were a generous gift from Paul L. Kaufman
(University of Wisconsin, Madison, WI). An immortalized HTM cell
line, TM5, was originally provided from Alcon Research Ltd (Fort
Worth, TX). Primary cultured cells from human retinal pigment epi-
thelum (RPE) were a gift from Don-Il Ham (Sungkyunkwan Univer-
sity, Seoul, Korea). Human embryonic kidney 293A cells and a
human neuroblastoma cell line, SH-SY5Y, were purchased from
Qbiogene (Carlsbad, CA) and Cell Line Bank (Seoul, Korea), respec-
tively. All cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum and antibiot-
ics (100 units/mL penicillin and 100 ug/mL streptomycin) at 37 C
in a humidiﬁed chamber with 5% CO2.5271 1012 GGTACCATCTTTGTTCAGTTTACCTC
GACACGTTATCCTTGTATGCC
Sequences are based on GenBank accession number AF007562. Underlined are
restriction enzyme sites for cloning.2.2. Northern blot hybridization
At the end of the culture, HTM cells were harvested and total
RNA was isolated using TRIzol reagent (Life Technologies, Rock-
ville, MD). Approximately 5 ug of total RNA was size fractionated
by electrophoresis on 1.2% agarose gel containing 2.2 M formalde-
hyde and 0.05 M 3-[N-morpholino] propane sulfonic acid (MOPS),
transferred to a nylon membrane, and cross-linked with UV irradi-
ation. The membrane was prehybridized for 2 h at 65 C in a
hybridization buffer composed of 0.5 M NaH2PO4, 1 mM EDTA,
7% SDS, and 1% bovine serum albumin, and then hybridized over-
night at the same temperature with a [32P]-labeled probes for hu-
manMYOC andMKP-1 in the hybridization buffer. The probes used
were labeled with a random primed DNA labeling kit (Amersham,
Piscataway, NJ). The template DNA for MYOC was obtained by
digesting the pDACMV-wild-type myocilin-GFP vector, which car-
ries the full-length myocilin cDNA fused to the N-terminus of the
green ﬂuorescent protein gene (Sohn et al., 2002). The gene for
MKP-1 was purchased from the Korean BioInformation Center
(Daejon, Korea). After hybridization, the membrane was washed
twice in 2X SSC-0.1% SDS, and then in 1X SSC-0.1% SDS, and auto-
radiographed at 70C using intensifying screens.2.3. MYOC promoter-luciferase chimeric constructs
A series of luciferase reporter plasmids containing progressive
deletions of the 50-ﬂanking sequence of human MYOC were made
as follows. The primers used to make constructs are shown in Table
1. Initially, 432 bp (367 to +65), 749 bp (684 to +65), and
1606 bp (1541 to +65) of the 50-ﬂanking region of MYOC were
ampliﬁed by polymerase chain reaction using the genomic DNA ex-
tracted from HTM cells as the template. After digestion with KpnI
and NheI, the ampliﬁed products were separately cloned into the
corresponding sites of the promoterless ﬁreﬂy luciferase expres-
sion vector, pGL3-basic (Promega), in the sense orientation. They
were designated pLuc 367, pLuc 684, and pLuc 1541, respectively.
To construct pLuc 2548, a 1230 bp fragment (2548 to1319) was
ampliﬁed and cloned between the KpnI and SpeI sites of the pLuc
1541 vector. Similarly, pLuc 3531 was constructed by amplifying
a 1085 bp fragment (3531 to 2447) and cloning it into the
KpnI/StuI sites of the pLuc 2548 vector. Then, a 942 bp fragment
(4351 to 3410) was ampliﬁed and cloned into the KpnI/Bst1107I
sites of the pLuc 3531 vector to produce pLuc 4351. Finally, a
1012 bp fragment (5271 to4260) was ampliﬁed and cloned into
the KpnI/NsiI sites of the pLuc 4351 vector, yielding pLuc 5271. The
ﬁdelity of all the constructs was veriﬁed by DNA sequencing.2.4. Luciferase reporter gene analysis
Cells were plated into a 24-well plate, grown to a 60–70% con-
ﬂuence, and transiently transfected with 500 ng of the reporter
plasmid using a novel gene delivery agent, PAMAM-Arg, which is
a polyamidoamine (PAMAM) dendrimer grafted with arginine res-
idues (Choi et al., 2004). As an internal reference for transfection
efﬁciency, 20 ng of pRL-TK (Promega), which expresses moderate
levels of Renilla luciferase, was cotransfected. Seventy-two hours
after transfection, the cells were lysed with 40 ul of passive lysis
buffer (Promega) and harvested by scraping with a cell lifter. After
brief centrifugation, the supernatants were recovered and sub-
jected to consecutive assays for ﬁreﬂy luciferase activity and Renil-
la luciferase activity using the Dual-Luciferase Reporter Assay
System (Promega) and a Turner Designs TD-20/20 Luminometer
(Promega) according to the manufacturer’s instructions.
3. Results
To analyze the time course ofMYOC expression in vitro, primary
HTM cells were cultured to conﬂuence and exposed to 100 nM DEX
for periods ranging from 12 h to 7 days. Northern blot analysis re-
vealed that the steady-state level ofMYOCmRNA increased contin-
uously over time, but there was an apparent delay in the initiation
of MYOC transcription of approximately 12 to 24 h. The delayed
transcription was not noted in mitogen-activated protein kinase
phosphatase 1 (MKP1), a glucocorticoid-inducible gene that is
stimulated by a primary response mechanism (Fig. 1A). It has been
reported that the induction of MYOC by DEX is a secondary gluco-
corticoid response that shows a delayed time course compared
with that of the primary response (Shepard et al., 2001). Because
the delayed secondary response acts indirectly on target gene tran-
scription and requires de novo protein synthesis, we determined
the extent to which DEX-mediated MYOC induction is blocked by
cycloheximide (CHX), a protein synthesis inhibitor. In the presence
of CHX, MKP1, which has a tendency to be upregulated by treat-
ment with CHX (Aghaloo, Pirih, Shi, Bezouglaia, & Tetradis, 2006),
was induced more strongly. However, under the same conditions,
no MYOC expression was observed even 4 days after induction
(Fig. 1B).
To determine the kinetics of MYOCmRNA decay in vitro, conﬂu-
ent HTM cells were pretreated with 100 nM DEX for 5 days and
cultured in the absence of DEX for the appropriate lengths of time.
At least half the MYOC mRNA was detected up to 4 days after the
Fig. 2. Proﬁles of MYOCmRNA degradation in HTM cells. Cells were pretreated with
100 nM DEX for 5 days and then further cultured for the times indicated (A) in the
absence of DEX or (B) in the presence of 10 ug/mL ActD with or without 100 nM
DEX. MYOC mRNA was detected by northern blot analysis. The same blots were
stripped and re-hybridized with a probe for MKP1 mRNA. Total RNA stained with
ethidium bromide is shown as the loading control.
Fig. 1. Proﬁles of MYOC induction in cultured HTM cells. Primary human HTM cells
were cultured to conﬂuence and exposed to 100 nM DEX (A) in the absence or (B) in
the presence of 20 ug/mL CHX for the times indicated. MYOC expression was then
detected by northern blot analysis. The same blots were stripped and re-hybridized
with a probe for MKP1 mRNA. Total RNA stained with ethidium bromide is shown
as the loading control.
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graded in less than 1 day under the same conditions (Fig 2A). It is
possible that MYOC is continuously stimulated after chase because
it is induced by a secondary response mechanism. To rule out this
possibility, MYOC mRNA degradation was also monitored in the
presence of the RNA synthesis inhibitor actinomycin D (ActD).
Without its de novo synthesis, approximately half the MYOCmRNA
could still be detected after 4 days following chase. In contrast,
MKP1 mRNA was nearly completely degraded in less than 1 day.
DEX had little effect on the steady-state level of eitherMYOCmRNA
or MKP1 mRNA, conﬁrming that new RNA synthesis was com-
pletely inhibited by ActD (Fig. 2B).
To identify the cis element responsible for MYOC transcription,
the transient expression of a set of reporter constructs containing
variable lengths of the 50 upstream sequence of MYOC was ana-
lyzed in the presence and absence of DEX. The differences in the
luciferase activity of the lysates from untreated and DEX-treated
cells are shown in Fig. 3. Although a moderate increase in lucifer-
ase activity was observed with constructs increasing in length up
to 1541 bp, a major increment in transcription activity was ob-
tained with construct pLuc 2548, which contains 2548 bp relative
to the transcriptional start site. The extent of luciferase induction
by DEX did not increase further with constructs increasing in
length up to 5272 bp. Therefore, the region between base pairs2548 and 1541 in the 50-ﬂanking sequence of the MYOC gene
is primarily responsible for the induction of luciferase activity by
DEX. The importance of the region positioned between 2548 bp
and 1541 bp, in terms of responsiveness to DEX, was identiﬁed
in another HTM cell line which was isolated from an independent
individual donor (data not shown). To test whether the DEX-
responsive transcription observed with pLuc 2548 is speciﬁc to
HTM cells, comparisons were made with other cell lines such as
TM-5, 293A, SH-SY5Y, and RPE cells (Fig. 4). A signiﬁcant increase
in luciferase activity with DEX treatment was observed in HTM
cells, but not in the other cell lines including the primary RPE cells.
These results are consistent with the earlier ﬁnding that MYOC is
inducible by exposure to glucocorticoids only in cultured TM cells
or TM tissues from perfused organ cultures (Nguyen et al., 1998;
Polansky et al., 1997).
4. Discussion
In this study, we investigated the glucocorticoid responsiveness
of the glaucoma gene MYOC within several cellular contexts. We
have shown here that the MYOC gene is responsive to DEX via a
secondary glucocorticoid-response mechanism that is mediated
by a cis-acting element located between nucleotide positions
2548 and 1541, which appears functionally active only in
HTM cells. These results provides an important complement to
Fig. 3. Deletion analysis of DEX-responsive elements of MYOC in HTM cells. Shown on the left are the deletions, with numbers indicating the positions of the 50-ﬂanking
sequences of MYOC relative to the putative transcription initiation site. HTM cells were cotransfected with a series of deleted reporter plasmids and pRL-TK and cultured in
the presence or absence of 100 nM DEX. After 72 h, the cell lysates were assayed for ﬁreﬂy luciferase and Renilla luciferase activities. Transfection efﬁciency was normalized
to the Renilla luciferase activity. The ﬁreﬂy luciferase activity in the lysates of the DEX-treated cells relative to the activity in the lysates of the untreated cells is shown as the
fold induction of luciferase by DEX on the right side. Similar results were obtained in three separate experiments. Each column and bar represents the mean ± S.E.M. of three
wells. P < 0.01 vs control (Dunnett’s test).
Fig. 4. Cell speciﬁcity of DEX-responsive elements of MYOC. Cells were cotrans-
fected with pLuc 2548 and pRL-TK and cultured in the presence or absence of 100
nM DEX. After 72 h, the cell lysates were assayed for ﬁreﬂy luciferase and Renilla
luciferase activities. Transfection efﬁciency was normalized to the Renilla luciferase
activity. The ﬁreﬂy luciferase activity in the lysates of the DEX-treated cells relative
to the activity in the lysates of the untreated cells is shown as the fold induction of
luciferase by DEX. Similar results were obtained in three separate experiments.
Each column and bar represents the mean ± S.E.M. of three wells. P < 0.01 vs
control (Dunnett’s test).
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responsive gene that has the intriguing feature of being expressed
in TM cells in vitro or TM tissues from organ cultures in vivo (Ngu-
yen et al., 1998; Polansky et al., 1997; Shepard et al., 2001).
An additional important ﬁnding, in terms ofMYOC expression, is
the extraordinary stability of MYOC mRNA. Not only the control of
the transcriptional rate, but also the modulation of mRNA stability
is a key to the regulation of gene expression, determining the
quantity of transcripts that are available for translation (Keene,2007). Generally, the half-lives of mRNAs of inducible genes are
short relative to those of housekeeping genes (Lam et al., 2001).
However, the half-life of MYOC mRNA induced by DEX is several
times longer than 7.1 h, the estimated median half-life of genomes
in embryonic stem cells, as calculated with microarray-based anal-
ysis (Sharova et al., 2009). We have also reported that myocilin
protein is intrinsically very stable in HTM cells and conditioned
medium (Sohn et al., 2009). The high stability of both the mRNA
and protein products of theMYOC gene explains why its expression
increased continuously in DEX-treated HTM cells in proportion to
the time exposed.
Although the causative role of MYOC in the pathogenesis of SIG
remains controversial, some evidence suggests that the high levels
of myocilin increase the eye’s outﬂow resistance and, therefore,
leads to the elevation of IOP (Fautsch et al., 2006, Wentz-Hunter,
Shen, Okazaki, Tanihara, & Yue, 2004). On the contrary, an in vivo
study revealed that, although transgenic lines expressed high
MYOC levels to a degree similar to that induced by glucocorticoid,
they failed to produce elevated IOP or glaucoma, suggesting that
increased MYOC expression, in itself, might be insufﬁcient to dis-
play the glaucoma phenotype (Gould et al., 2004). Recently, we
were unable to identify any clinical correlation between the po-
tency of MYOC induction and the degree of IOP elevation among
those eye drops that contain steroids (Sohn et al., 2010). Therefore,
we are hard-pressed to explain the precise relationship between
MYOC expression and SIG development at this time. Nonetheless,
our study shows thatMYOC expression could be an important mar-
ker of the extent of exposure to glucocorticoids.
The marked responsiveness of MYOC to glucocorticoid has been
well documented for more than 10 years. Consequently, certain
groups have attempted to identify functional glucocorticoid-
responsive region(s) in the promoter region of MYOC (Fingert
et al., 2001, Kirstein, Cvekl, Chauhan, & Tamm, 2000; Shepard
et al., 2001). To date, they have failed to identify any glucocorti-
coid-responsive region in the MYOC promoter, because of certain
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mely low transfection efﬁciency of primary HTM cell cultures
(Hoffman, Conley, Stamer, & McKay, 2005). In this study, we
screened different kinds of transfection reagents to optimize the
transfection efﬁciency. Of the various reagents used, PAMAM-Arg,
which is composed of a backbone of PAMAM dendrimer and a sur-
face covered with basic L-arginine residues, worked best with cul-
tured HTM cells (Choi et al., 2004). Under the optimized conditions
for cell transfection, our reporter construct, pLuc 2548, which con-
tains 2548 bp relative to the transcriptional initiation site, revealed
an approximately threefold increase in luciferase activity in DEX-
treated cells.
However, even taking into account the low transfection efﬁ-
ciency of HTM cells, the transcriptional activity of pLuc 2548 was
still low compared with that of other DEX-responsive genes. This
suggests that the regulatory elements of MYOC may be relatively
weak in terms of promoter strength, making it more difﬁcult to
identify cis-acting element in theMYOC promoter. Despite this dif-
ﬁculty, we identiﬁed an important regulatory region positioned be-
tween 2548 bp and 1541 bp in the 50-ﬂanking sequences of
MYOC. The presence of this region led to an apparent increase in
luciferase activity in DEX-treated cells. The HTM-cell-speciﬁc
responsiveness of the region to DEX treatment was consistent with
the results of Northern blot hybridization, indicating that our pro-
moter analysis was reliable. It also indicates that some TM- or tis-
sue-speciﬁc factors may be required for the cell-type-dependent
transactivation of MYOC by DEX.
Until now, many investigators have focused on whether MYOC
upregulation is related to SIG development. We have shown that
MYOC expression alone warrants investigation beyond the scope
of glaucoma research. The glucocorticoid responsiveness of MYOC
has certain notable properties, including its delayed secondary
responsiveness, the extraordinary stability of MYOC mRNA, and
its tissue-speciﬁc inducibility. MYOC induction by DEX is deﬁnitely
required for new protein synthesis from the primary response
gene(s). Here, we have identiﬁed a cis-acting region for secondary
glucocorticoid responsiveness on the MYOC promoter. The region
may contain element(s) which bind(s) factor(s) induced by gluco-
corticoids. This is a major step towards understanding the distinc-
tive pattern of MYOC expression and identifying new cis- and
trans-activating elements involved in MYOC induction following
glucocorticoid treatment. Further studies of MYOC expression
may provide deﬁnitive clues to the role of myocilin in the patho-
genesis of SIG, a role that has thus far remained elusive.5. Conclusions
Our data demonstrate that DEX-induced MYOC expression is a
secondary glucocorticoid response, which is mediated by a TM cell-
or TM-tissue-speciﬁc element(s). A region between the base pairs
2548 and 1541 in the 50-ﬂanking sequences of the MYOC in-
cludes cis-elements that are responsible for the secondary gluco-
corticoid response. In addition, MYOC mRNA is intrinsically quite
stable, rendering an increase in transcripts in HTM cells propor-
tional to the time of exposure to glucocorticoid. The extraordinary
stability of MYOC mRNA may be an important mechanism for
increasing the level of steady-state mRNA, even though its tran-
scriptional level is low.Acknowledgments
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